Tag: Prescription Drugs

Displaying 1 - 7 of 7 results.

Filtering by content type: Blog Post

The ability to appoint a monitor is an important tool in building a successful merger remedy. The boilerplate-style language FTC uses in merger orders when appointing a monitor belies the unique and varied roles that monitors play in assuring that the order maintains or restores...
FTC staff has doggedly tracked down information about competition in the pet medications industry for the past several years. Why? Because it’s a large and growing consumer market. With 65 percent of American households owning a pet, and retail sales of prescription pet medications...
Consumers frequently contact the Bureau of Competition to alert us that the cost of a prescription drug suddenly spiked up, and ask if the FTC can take antitrust action to bring the price back down. The answer in a nutshell is that it depends on the reason for the price change...
In a recently published article, we discuss our finding that generic drug companies successfully use low-pricing strategies to discourage entry by new competitors in certain circumstances.
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines. You can view a live webcast of the workshop on the FTC’s website, or follow live tweets...
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin,...